Targeting Fibroblast Growth Factor 23 Signaling with Antibodies and Inhibitors, Is There a Rationale?

RT @divyaa24: @Nephro_Sparks @GeorgeVasquezR2 @ginsbergcharles @RenalFellowNtwk @javo_neyra @pranavgarimella @IsaacPh06634447 @ISNkidneycar…

@Nephro_Sparks @GeorgeVasquezR2 @ginsbergcharles @RenalFellowNtwk @javo_neyra @pranavgarimella @IsaacPh06634447 @ISNkidneycare @slunephrons Can Burosumab (anti FGFantibody) help pts with CKDMBD where most of the treatments have focussed on surrogate endpoi

RT @Osteoporosis_NL: Targeting Fibroblast Growth Factor 23 Signaling with Antibodies and Inhibitors, Is There a Rationale? Fukumoto S Front…

Targeting Fibroblast Growth Factor 23 Signaling with Antibodies and Inhibitors, Is There a Rationale? Fukumoto S Front Endocrinol (Lausanne). 2018 Feb 20;9:48 https://t.co/nsucuZuMGw doi: 10.3389/fendo.2018.00048 DIA FGF23-related hypophosphatemic disease